Altogether, these data highlight that targeting the S1P axis might be valuable as a therapeutic strategy for glioma/GBM patients, suggesting the potential of S1PR inhibitors such as Fingolimod [27]. This evidence concerns the gene MBTPS1 and glioblastoma.